Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615179 · ClinicalTrials.gov registry record
Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 4,545
- Enrollment target
NCT07615179: Completed study, sponsored by Sanofi.
NCT07615179 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 4,545 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07615179 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 4,545 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.
Interventions
- DRUG Alirocumab
- DRUG Comparator: No PCSK9i Therapy (either mAb or siRNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,545 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2026-05-30 |
What the finished NCT07615179 record still lists
NCT07615179 is an observational study that tracks outcomes without assigning an intervention. Its 4,545 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Alirocumab is the first listed.
NCT07615179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07615179 about?
NCT07615179 is a clinical study titled "Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)". The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PC...
What is the current status of trial NCT07615179?
This trial is currently completed. The enrollment target is 4,545 participants. The study started on 2025-02-17. Estimated completion is 2026-05-30.
What interventions are being tested in trial NCT07615179?
The interventions under investigation include: Alirocumab (DRUG), Comparator: No PCSK9i Therapy (either mAb or siRNA) (DRUG).
Who is sponsoring clinical trial NCT07615179?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702878 · 4,514 participants · Phase 3
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI